Monday, June 28, 2021

Cocrystal Pharma Inc. (COCP)
Cocrystal Announces CC-42334 To Start Clinical Studies in Influenza

Cocrystal Pharma Inc is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. The company employs structure-based technologies and Nobel Prize-winning expertise to create first-and best-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks.

Robert LeBoyer, Senior Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

The Product Pipeline Advances Cocrystal announced that it has completed studies to file an IND for CC-42344, its PB2 inhibitor for the treatment of seasonal and pandemic influenza A.  The first Phase 1 study is planned for 3Q21.


CC-42334 Has A Unique Mechanism Of Action CC-42334 was developed using Cocrystal’s proprietary anti-viral technology, targeting an enzyme early in the process of producing the next viral generation.  This differs from other anti-influenza approaches that are based on stimulating an immune response or blocking viral surface proteins …

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary.  Proper due diligence is required before making any investment decision.